A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to EudraCT 2016-004942-27, EWALL-INO; P16/11: A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia. (Principal Investigator: doc. MUDr. Mgr. Cyril Šálek, Ph.D., cyril.salek@uhkt.cz). Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia